Assertio (ASRT) Projected to Post Quarterly Earnings on Monday

Assertio (NASDAQ:ASRT - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $27.52 million for the quarter.

Assertio Stock Performance

ASRT traded down $0.01 during trading on Wednesday, reaching $0.65. 119,766 shares of the company's stock were exchanged, compared to its average volume of 713,644. The company has a quick ratio of 1.57, a current ratio of 2.01 and a debt-to-equity ratio of 0.30. The business has a 50 day moving average price of $0.69 and a 200 day moving average price of $0.84. Assertio has a fifty-two week low of $0.51 and a fifty-two week high of $1.80. The company has a market capitalization of $62.21 million, a P/E ratio of -0.89, a PEG ratio of 3.25 and a beta of 0.56.

Wall Street Analysts Forecast Growth

ASRT has been the topic of a number of research reports. Industrial Alliance Securities set a $1.75 target price on shares of Assertio in a research report on Friday, March 14th. HC Wainwright decreased their price target on shares of Assertio from $4.00 to $3.50 and set a "buy" rating for the company in a research note on Wednesday, March 19th. Finally, StockNews.com raised Assertio from a "hold" rating to a "buy" rating in a report on Monday, April 14th.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.